Last reviewed · How we verify
NCT06108037
DHL Survey on Generative AI for MyChart Messaging
NA trial testing Generative AI for electronic communication and disclosure in Communication in 1,454 participants. Completed in 11 December 2023.
11 December 2023
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 1,454 |
| Start date | 31 October 2023 |
| Primary completion | 11 December 2023 |
| Estimated completion | 11 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Generative AI for electronic communication and disclosure
Conditions studied
- Communication — all drugs for Communication →
Sponsor
Duke University
Who can join
18 and older, any sex, with Communication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to understand how patients feel about the use of computer programs to create responses when they send electronic messages to their doctors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06108037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Communication
Currently open trials in the same condition.
- NCT07303517 — AI-Driven Consent Simplification Study · recruiting
- NCT07215507 — Timing of Physician Rounds for Antepartum Patients · NA · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting
- NCT07137377 — Assessing the Impact of Therapeutic Communication on Patients' Anxiety During Elective Cesarean Sections · NA · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06108037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 13 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing